Wai Hong Wilson Tang, MD, FACC
Professor of Medicine

Printed as of 11/20/2026

Disclosures

Personal Commercial (23)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Alnylam Pharmaceuticals	Research/Research Grants ‡ *APOLLO-B / HELIOS-B*	None ($0)	*Heart Failure and Cardiomyopathies*
Applied Therapeutics, Inc	Research/Research Grants ‡ *Steering Committee member for ARISE-HF (AT-001 for Diabetic Cardiomyopathy)*	None ($0)	*Prevention*
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ *Site-PI for the ENDEAVOR study*	None ($0)	*Heart Failure and Cardiomyopathies*
Belvoir Media Group	Other - *Editorship/Authorship*	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
BioCardia Inc	Research/Research Grants ‡ *Site PI for CardiAMP Heart Failure Trial*	None ($0)	*Heart Failure and Cardiomyopathies*
Boston Scientific	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Bristol-Myers Squibb Company	Research/Research Grants ‡ *Site-PI for Danicamtiv MYK491-006 Study*	None ($0)	*Heart Failure and Cardiomyopathies*
CardiaTec Biosciences	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Cardiol Therapeutics, Inc	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Cardurion Inc	Research/Research Grants ‡ *Site-PI for CARDINAL-HF study*	None ($0)	*Heart Failure and Cardiomyopathies*
Cordio Medical Ltd	Research/Research Grants ‡ *Site PI for DETECT-HF study*	None ($0)	*Heart Failure and Cardiomyopathies*
Genomics, Inc	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Intellia Therapeutics	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Kiniksa Pharmaceuticals	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Renovacor, Inc	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Salubris Biotherapeutics, Inc.	Research/Research Grants ‡ *PI of JK07 Phase I Study*	None ($0)	*Heart Failure and Cardiomyopathies*
Second Heart Assist, Inc	Research/Research Grants ‡ *PI of Second Heart Assist Device Early Feasibility Study for Cardio-Renal Syndrome*	None ($0)	*Heart Failure and Cardiomyopathies*
Sequana Medical, AV	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Springer Publishing	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Tenaya Therapeutics Inc	Research/Research Grants ‡ *Seruprevalence study for PKP2-associated ARVC patients*	None ($0)	*Heart Failure and Cardiomyopathies*
WhiteSwell Inc	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Zehna Therapeutics, LLC	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Spouse/Domestic Partner/Immediate Household Member			
Cardiac Community Core Lab, LLC	Consultant Fees/Honoraria	Modest (< $5,000)	*Invasive CV Angio and Interventions*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
American Board of Internal Medicine	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Non-Commercial Enity Name	Relationship Category	Compensation Level	*Topic Area(s)*
† none			
NIH	Research/Research Grants	Significant (>= $5,000)	*Prevention Heart Failure and Cardiomyopathies Noninvasive Imaging*
Springer Nature	Other - *Author/Editor*	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*

Clinical Trial Enroller (7)

Trial Name	Trial Sponsor	Trial Funding Source
ALN-TTR02-011 (APOLLO-B)	Alnylam Pharmaceuticals	
ALN-TTRSC02-003 (HELIOS-B)	Alnylam Pharmaceuticals	
ENDEAVOR	AstraZeneca Pharmaceuticals	
CardiAMP™ Cell Therapy Heart Failure Trial	BioCardia Inc	
Danicamtiv for Genetic Dilated Cardiomyopathy	Bristol-Myers Squibb Company	
HearO Trial	Cordio Medical Inc	
REALM-DCM (ARRY797-301)	Pfizer Inc	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/12/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/12/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/12/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/12/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.